Diabetes management can be a major factor in renal transplant aftercare; can DPP-4 therapy help improve outcomes?
Read More »Sitagliptin Associated With Reduced Mortality In Diabetes Patients With COVID-19
Patients taking the DPP-4 inhibitor sitagliptin had lower risk of needing intensive care or needing mechanical ventilation.
Read More »Another Oral Combination Antidiabetic Agent
Dual and triple therapy just got a little easier.
Read More »Do DPP-4 Inhibitors Increase Risk of Pneumonia in Patients with T2D?
Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.
Read More »Examining the Risks of Antihyperglycemic Dual and Triple Therapies for T2D
A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.
Read More »Could a Diabetes Medication Affect COVID-19 Outcomes?
Research into the interaction of DPP4 and coronavirus may be a step toward a cure.
Read More »New CV Outcomes Trials Examine Linagliptin and Glimepiride Among Patients With High CVD Risk
The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.
Read More »FDA Approves a Triple Therapy for Type 2 Diabetes in One Tablet
More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.
Read More »Dapagliflozin vs. Saxagliptin: Durability of Glycemic Control
The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.
Read More »New Approved Complete Diabetes Regimen in One Tablet
Diabetes has never been simpler to control with this once daily pill.
Read More »